In addition, the target genes of ICB and lenvatinib were significantly enriched in terms of the functional pathways of immune-related genes, including PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway, positive regulation of cell adhesion, T cell activation, and leukocyte proliferation. The gene discussed is CD274; the disease is cancer.